Allergia, Inc. v. Bouboulis et al
Filing
76
ORDER denying 59 Defendant's Motion for Advancement of Legal Expenses. Signed by Judge Janis L. Sammartino on 1/19/2017. (kcm)
1
2
3
4
5
6
7
8
UNITED STATES DISTRICT COURT
9
SOUTHERN DISTRICT OF CALIFORNIA
10
11
12
ALLERGIA, INC., a California
corporation,
15
ORDER DENYING DEFENDANT’S
MOTION FOR ADVANCEMENT OF
LEGAL EXPENSES
Plaintiff,
13
14
Case No.: 14-CV-1566 JLS (RBB)
v.
DENIS BOUBOULIS, an individual; and
DOES 1 THROUGH 5, inclusive,
16
(ECF No. 59)
Defendants.
17
18
19
Presently before the Court is Defendant Denis Bouboulis’ Motion for Advancement
20
of Legal Expenses. (“Mot.,” ECF No. 59.) Also before the Court is Plaintiff Allergia,
21
Inc.’s Response in Opposition to, (“Opp’n,” ECF No. 62), and Defendant’s Reply in
22
Support of, (“Reply,” ECF No. 64), Defendant’s Motion. Plaintiff also filed an untimely
23
supplemental response in opposition. (“Supp. Opp’n,” ECF No. 63.) The Court vacated
24
the hearing on the Motion scheduled for August 25, 2016 pursuant to Civil Local Rule
25
7.1(d)(1). (ECF No. 65.) After considering the parties’ arguments and the law, the Court
26
DENIES Defendant’s Motion for Advancement of Legal Expenses.
27
///
28
///
1
14-CV-1566 JLS (RBB)
1
BACKGROUND
2
Beginning several years ago, Defendant worked with Plaintiff’s predecessor-in-
3
interest, CLRS Technology, Inc., to develop and invent medical devices and related
4
methods for using phototherapeutics to alleviate the symptoms of allergic rhinitis. (Second
5
Amended Complaint (“SAC”) ¶ 9, ECF No. 53.) In exchange for these contributions,
6
Defendant received 116,111 shares of CLRS common stock. (Id.)
7
On August 5, 2010, CLRS filed a provisional patent application with the United
8
States Patent and Trademark Office (USPTO), Application Ser. No. 61/371,172 (the “’172
9
Application”), directed to an invention for alleviating the symptoms of allergic rhinitis.
10
(Id. ¶ 10.) Defendant was one of three named inventors. (Id.)
11
Approximately two months later, CLRS spun out ownership of the ’172 Application
12
to Plaintiff in connection with a corporate transaction involving a third party, Solta. (Id.
13
¶ 11.) Accordingly, Plaintiff was incorporated on October 5, 2010 under the laws of
14
California.
15
Defendant—received shares of stock in Plaintiff based on their then-existing shares in
16
CLRS. (Id.) Defendant was made Plaintiff’s President. (See id. ¶ 16.)
(Id. ¶ 12.)
All of the then-existing shareholders of CLRS—including
17
CLRS then assigned all its rights in the ’172 Application to Plaintiff. (Id. ¶ 13.) On
18
October 12, 2010, Defendant signed the Assignment and Assumption Agreement (the
19
“Assignment Agreement”) on behalf of Plaintiff. (Id. ¶¶ 14–15.) The Assignment
20
Agreement provided that “Assignor [CLRS] owns all of the assets set forth on Exhibit A
21
attached hereto (the “Distributed Assets”) . . . [,]” (id. ¶ 15(a) (emphasis in original)), which
22
included the ’172 Application, (id. ¶ 15(d)). Pursuant to the Assignment Agreement, CLRS
23
and Plaintiff desired to effect “the sale, assignment, transfer, conveyance, distribution and
24
delivery of all of Assignor’s rights, title and interest in, to or under the Distributed Assets
25
to Assignee [. . . Allergia]” and, “at the request of a party [to the Agreement] and without
26
further consideration, the other party . . . shall execute and deliver . . . such other
27
instruments of assignment . . . as such party may reasonably request to effect the
28
distribution by [CLRS] of the Distributed Assets.” (Id. at ¶¶ 15(b), (c)). On October 13,
2
14-CV-1566 JLS (RBB)
1
2010, Defendant also signed the License Agreement on behalf of Plaintiff. (Id. at ¶¶ 16–
2
17.) The License Agreement expressly represented that CLRS “hereby assigned to
3
[Plaintiff] all right, title and interest in and to the ATD Patent Rights,” which was defined
4
as including the ’172 Application. (Id. ¶¶ 17(a), (c).)
5
When signing the Assignment and License Agreements, “Defendant was fully aware
6
of the contents of the documents . . . , and was fully aware of the purpose and intent of
7
those documents.” (Id. ¶ 18.) “Defendant gave no indication to Plaintiff . . . that Defendant
8
believed that CLRS and then [Plaintiff] did not own all of the ’172 [Application] and
9
related rights, and/or that Defendant believed that he had not assigned his rights therein to
10
CLRS and then/thereby to [Plaintiff].” (Id. ¶ 19.) Indeed, “for at least many months . . . ,
11
Defendant . . . did not tell or indicate to [Plaintiff] . . . that Defendant . . . believed that he
12
personally retained any ownership in the ‘172 [Application] and related rights,” but rather
13
he “remained silent on the issue.” (Id. ¶ 24.)
14
On October 15, 2010, the initial incorporator of Plaintiff formally named Defendant
15
as an initial director of Plaintiff. (Id. ¶ 20.) On that same date, the CLRS/Solta transaction
16
was executed. (Id. ¶ 21.) The resulting Agreement and Plan of Merger (the Executive
17
Summary) and Disclosure Schedule expressly referenced the Assignment and License
18
Agreements. (Id. ¶¶ 21–22.)
19
A few months later, Defendant requested a telephone conference with the owners
20
and directors of Plaintiff, during which he disclosed an outline of a strategic business plan
21
for Plaintiff. (Id. ¶ 27.) Defendant proposed that he would undertake execution of the
22
proposed plan and assume the duties of CEO of Plaintiff if he were granted a controlling
23
stake in the capital stock of Plaintiff. (Id.) In response, the shareholders and directors of
24
Plaintiff requested that Defendant prepare and present a budget for his proposal. (Id. ¶ 28.)
25
Several months passed without Defendant making the requested presentation.
26
Instead, Defendant “secretly prepared a related and apparently competitive patent
27
application . . . without the knowledge and/or authorization of [Plaintiff] or its other
28
shareholders.” (Id. ¶ 29.) Defendant continued as President and director of Plaintiff until
(Id.)
3
14-CV-1566 JLS (RBB)
1
approximately May 2011. (Id. ¶ 30.)
2
On August 4, 2011, Plaintiff filed a full utility application, Ser. No. 13/198,672 (the
3
“’672 Application”). (Id. ¶ 34.) Although Plaintiff solicited Defendant’s signature on
4
related filings, Defendant refused to participate or assist in the prosecution of the ’672
5
Application. (Id.)
6
On August 5, 2011, Defendant secretly filed Application Ser. No. US 13/204,282
7
(the ’282 Application). (Id. ¶¶ 29, 35.) The ’282 Application “is so closely related to [the
8
’172 Application] that it may foreseeably interfere with or negatively affect [Plaintiff]’s
9
business efforts related to [Plaintiff]’s patent-pending technology.” (Id. ¶ 29.) Defendant
10
filed a related Patent Cooperation Treaty patent application, Ser. No. PCT/US12/049108
11
(the “’108 Application”), on August 1, 2012, and a related European Union application,
12
Ser. No. 2,739,354 (the “’354 Application”), on February 26, 2014.
13
“Defendant’s patent applications include description and claims that are similar or even
14
virtually identical to the description and claims . . . in the Plaintiff’s pending patent
15
applications.” (Id. ¶ 37.)
(Id. ¶ 36.)
16
Plaintiff subsequently has “continued to make reasonable efforts to get Defendant to
17
sign certain formal ‘assignment’ documents related to the ’172 [Application],” but
18
Defendant has refused. (Id. ¶ 39.) “[P]otential investors in Plaintiff’s ’172 patent-pending
19
technologies and related opportunities have declined to invest based on Defendant[’s] . . .
20
actions, including positions taken and communicated to those investors by Defendant . . .
21
regarding the parties’ respective rights regarding Plaintiff’s ’172 patent-pending
22
technologies and related opportunities.” (Id. ¶ 40.)
23
On June 30, 2014, Plaintiff filed its initial complaint, asserting two causes of action:
24
(1) declaratory judgment of patent application ownership and/or other patent and
25
intellectual property rights, and (2) breach of fiduciary duty. (See ECF No. 1.) On August
26
17, 2015, the Court dismissed Plaintiff’s first cause of action to the extent it attempted to
27
correct ownership of the ’282 Application and its second cause of action for breach of
28
fiduciary duty. (See ECF No. 28.) Plaintiff filed its FAC on September 4, 2015 (see ECF
4
14-CV-1566 JLS (RBB)
1
No. 30), and on May 19, 2016 the Court dismissed Plaintiff’s causes of action for breach
2
of contract and fraud. (See ECF No. 51.)
3
On June 3, 2016, Plaintiff filed its SAC, alleging causes of action for (1) declaratory
4
judgment of patent application ownership and/or other patent and intellectual property
5
rights; (2) breaches of fiduciary duty and/or implied contract; and (3) fraud.
6
Defendant now moves this Court for advancement of legal expenses because
7
Defendant argues that Plaintiff sued him in his capacity as a former officer or director of
8
Plaintiff, and thus he is entitled to an advancement of fees pursuant to California
9
Corporations Code section 317 and Plaintiff’s Bylaws. The indemnification provision of
10
Plaintiff’s Bylaws states:
11
Section 6.1. Right to Indemnification. The Corporation shall
indemnify and hold harmless, to the fullest extent permitted by
applicable law as it presently exists or may hereafter be amended,
any person who was or is made or is threatened to be made a
party or is otherwise involved in any action, suit or proceeding,
whether civil, criminal, administrative or investigative (a
“proceeding”) by reason of the fact that he, or a person for whom
he is the legal representative, is or was a director or officer of the
Corporation or is or was serving at the request of the Corporation
as a director, officer, employee or agent of another corporation
or of a partnership, joint venture, trust, enterprise or nonprofit
entity, including service with respect to employee benefit plans,
against all liability and loss suffered and expenses (including
attorneys’ fees) reasonably incurred by such person. The
Corporation shall be required to indemnify a person in
connection with a proceeding (or part thereof) initiated by such
person only if the proceeding (or part thereof) was authorized by
the Board of Directors of the Corporation.
12
13
14
15
16
17
18
19
20
21
22
23
24
(Mot. Ex. B (“Bylaws”) 8,1 ECF No. 59-4.)
25
///
26
///
27
28
1
Pin citations refer to the CM/ECF numbers stamped electronically at the top of each page.
5
14-CV-1566 JLS (RBB)
Plaintiff’s Bylaws also provide an advancement provision, which states:
1
2
Section 6.2. Prepayment of Expenses. The Corporation shall
pay the expenses (including attorneys’ fees) incurred by a
director or officer in defending any proceeding in advance of its
final disposition, provided, however, that, to the extent required
by law, such payment of expenses incurred by a director or
officer in advance of the final disposition of the proceeding shall
be made only upon receipt of an undertaking by the director or
officer to repay all amounts advanced if it should be ultimately
determined that the director or officer is not entitled to be
indemnified under this Article or otherwise.
3
4
5
6
7
8
9
10
(Id.) Section 6.3 of the Bylaws further explains what a claimant must do if he is not
11
indemnified in full within sixty days of his written claim for indemnification. (Id.)
LEGAL STANDARD
12
13
California Corporations Code section 317 provides mechanisms for permissive and
14
mandatory indemnification by the corporation, as well as provisions for advancement of
15
expenses. Of issue here is the indemnification provision of subsection (c), which provides
16
that
17
18
19
20
21
22
[a] corporation shall have power to indemnify any person who
was or is a party or is threatened to be made a party to any
threatened, pending, or completed action by or in the right of the
corporation to procure a judgment in its favor by reason of the
fact that the person is or was an agent of the corporation, against
expenses actually and reasonably incurred by that person in
connection with the defense or settlement of the action if the
person acted in good faith, in a manner the person believed to be
in the best interests of the corporation and its shareholders.
23
24
25
26
27
28
Cal. Corp. Code § 317(c).
Subsection (f) further allows a corporation to advance fees in such cases:
[e]xpenses incurred in defending any proceeding may be
advanced by the corporation prior to the final disposition of the
proceeding upon receipt of an undertaking by or on behalf of the
agent to repay that amount if it shall be determined ultimately
6
14-CV-1566 JLS (RBB)
1
that the agent is not entitled to be indemnified as authorized in
this section. The provisions of subdivision (a) of Section 315 do
not apply to advances made pursuant to this subdivision.
2
3
4
Id. at § 317(f).
ANALYSIS
5
Defendant broadly argues that he is entitled to advancement of his fees based on
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
section 317(f) and Plaintiff’s Bylaws. (See generally Mot., ECF No. 59-1.) Plaintiff
responds that (1) Defendant is not entitled to advancement because he does not meet the
requirements of indemnification pursuant to section 317(c), on which Plaintiff believes the
advancement provision of section 317(f) is necessarily based, (Opp’n 11-13, ECF No. 62);
(2) advancement would be unfair given Defendant’s “extensive delay and litigation
tactics,” (id. at 13–14); (3) public policy should not permit advancement in this instance,
(id. at 14–16); (4) Defendant’s status as an officer or director of the company is irrelevant
to “Plaintiff’s main claims,” (id. at 7–11); and (5) in the alternative, Plaintiff should be
allowed to amend its complaint “to withdraw its claim for any rights under Defendant’s
other ‘secret’ patent applications,” (id. at 16–17). The Court considers each argument in
turn.
I.
Relationship
Between
Sections
317(c)
(Indemnification)
and
317(f)
(Advancement)
Defendant argues that sections 317(c) and 317(f) are conceptually and procedurally
separate provisions. (Mot. 13–16, ECF No. 59-1.) According to Defendant, section 317
indemnification is not available “until there has been either a determination of whether the
corporate agent was acting in good faith or an adjudication on the merits.” (Id.) On the
other hand, Defendant argues that advancement is a summary proceeding “that occurs
before any adjudication on the merits of the case against the corporate director or officer
and before any determination of ‘good faith.’” (Id. (emphasis in original).) “In other
words, the right to advancement does not depend on whether the corporate agent is
ultimately found to be entitled to indemnification.” (Id. at 14 (emphasis in original).)
7
14-CV-1566 JLS (RBB)
1
Plaintiff responds that, to the contrary, the advancement provision of section 317(f)
2
necessarily depends on section 317(c), and thus Defendant is not entitled to any
3
advancement because “there is no basis upon which he will ever be able to show that his
4
relevant actions . . . met the requirements for indemnification under 317(c).” (Opp’n 13,
5
ECF No. 62 (emphasis removed).)
6
Whether the advancement provision of section 317(f) is conceptually and
7
procedurally separate from section 317(c) appears to be a matter of first impression in
8
California. “When interpreting a statute, we look to the plain meaning of the statute’s
9
words, which are generally the most reliable indicator of the Legislature’s intent.”
10
Nicholas Labs., LLC v. Chen, 199 Cal. App. 4th 1240, 1249 (2011) (citing Cassady v.
11
Morgan, Lewis & Bockius LLP, 145 Cal. App. 4th 220, 231 (2006)).
12
Here, a plain reading of the statute supports Defendant’s view that the provisions are
13
conceptually and procedurally separate. The indemnification provisions require either an
14
ultimate determination that the agent was acting in good faith or an adjudication on the
15
merits. Subject to a few exceptions, section 317(c) broadly allows a corporation to
16
indemnify a corporate director or officer in any action “by reason of the fact” that they
17
were an agent of the corporation and an ultimate showing that they “acted in good faith, in
18
a manner the person believed to be in the best interests of the corporation and its
19
shareholders.” Cal. Corp. Code § 317(c). In addition, indemnification is mandatory under
20
section 317(d) if “a corporate agent has been successful on the merits in defense of any
21
proceeding referred to in subdivision (b) or (c) or in defense of any claim, issue, or matter
22
therein,” without regard to the officer’s good faith. Id. § 317(d). Thus, indemnification
23
under section 317 requires either a determination of the agent’s good faith or an
24
adjudication of success on the merits.
25
The advancement provision, in contrast, does not require any such determination.
26
While certainly related to the indemnification provisions, section 317(f) provides that any
27
such funds “may be advanced by the corporation prior to the final disposition of the
28
proceeding.” Cal. Corp. Code § 317(f) (emphasis added). Because advancement is
8
14-CV-1566 JLS (RBB)
1
permissive (i.e., a corporation “may” advance these funds), all that is required to satisfy
2
this subdivision is (1) corporate authorization for advancement (e.g., an advancement
3
provision in the corporation’s bylaws) and (2) “an undertaking by or on behalf of the agent
4
to repay that amount if it shall be determined ultimately that the agent is not entitled to be
5
indemnified as authorized in this section.”2 Id. Thus, whether or not the agent is ultimately
6
indemnified pursuant to section 317(c) has no bearing on whether the corporation has
7
authorized an advancement of those funds pursuant to subdivision (f).
8
The Court’s view of the statute comports with other jurisdictions that have
9
considered the same issue. See, e.g., Kaung v. Cole Nat. Corp., 884 A.2d 500, 509 (Del.
10
2005)3 (“An advancement action is a summary proceeding. The statutory authorization for
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
2
The Ninth Circuit also appears to agree with this view. Cf. Johnson v. Couturier, 572 F.3d 1067, 1078
(9th Cir. 2009) (noting that under section 317(f) “California allows advancement of defense costs upon
receipt of an undertaking,” and finding that but-for preemption under ERISA, director-defendants, who
were accused of corporate wrongdoing, “all submitted the requisite undertakings, thus apparently
rendering advancement of their defense costs enforceable under state law”).
3
In the absence of guidance from California courts, the Court finds Delaware law on advancement
particularly persuasive because of the depth of its experience with corporate governance issues. See, e.g.,
Int’l Airport Centers, L.L.C. v. Citrin, 455 F.3d 749, 752 (7th Cir. 2006) (Posner, J.) (“What is true is that
‘advancement’ is rather a Delaware specialty . . . .”); Stephen A. Radin, “Sinners Who Find Religion”:
Advancement of Litigation Expenses to Corporate Officials Accused of Wrongdoing, 25 Rev. Litig. 251,
251–52 (2006) (“Recent decisions in Delaware–‘the Mother Court of corporate law’ and the state whose
‘rich abundance of corporate law’ guides courts throughout the country due to ‘the special expertise and
body of case law developed in the Delaware Chancery Court and the Delaware Supreme Court’–address
an important but infrequently discussed corporate governance issue: charter, bylaw, and indemnification
or employment agreement provisions that mandate advancement of attorneys’ fees and other defense costs
for corporate directors, officers, and employees accused of wrongdoing by the corporation or by federal
or state law authorities.” (citations omitted)). Indeed, several other states interpreting their own
advancement and indemnification statutes have found Delaware law persuasive. See, e.g., Kramer v.
Liberty Prop. Trust, 408 Md. 1, 24–25 (2009) (“Due to [the similarity between both states’ advancement
statutes], and because the Delaware courts have gained a reputation for their expertise in matters of
corporate law, we deem decisions of the Delaware Supreme Court and Court of Chancery to be highly
persuasive as to our interpretation of what constitutes a ‘proceeding’ within the meaning of § 2-418
[Maryland’s advancement statute].”); Radin, supra, at 271 (“To the limited extent that there is law
[regarding advancement] outside Delaware, it is the same as the law in Delaware.”).
In addition, the Delaware corporate code provision providing for advancement is nearly the same
as California’s. Compare Cal. Corp. Code § 317(f), with Del. Corp. Code § 145(e); cf. Oakland Raiders
v. Nat’l Football League, 93 Cal. App. 4th 572, 586 n.5 (2001) (“The parties agree that we may properly
9
14-CV-1566 JLS (RBB)
1
interim advancement of litigation expenses is distinct from the right to receive final
2
indemnification under Section 145(a) and (b) of the DGCL.”); see also Miller v. Miller,
3
132 Ohio St. 3d 424, 429 (2012) (holding that, as a matter of first impression, “[a]lthough
4
advancement and indemnification are corollaries, they are not one and the same”); Ficus
5
Investments, Inc. v. Private Capital Mgmt., LLC, 61 A.D.3d 1, 9, 872 N.Y.S.2d 93 (2009)
6
(citing Delaware law as instructive and holding that indemnification and advancement are
7
“independent of one another, in that ‘an advancement proceeding is summary in nature and
8
not appropriate for litigating indemnification or recoupment’” (citation omitted)). Thus,
9
the Court rejects Plaintiff’s argument that Defendant’s right to advancement depends on
10
whether he will eventually be indemnified. See Heine v. Bank of Oswego, 144 F. Supp. 3d
11
1198, 1206 (D. Or. 2015) (citing Richard A. Rossman, Matthew J. Lund, and Kathy K.
12
Lochmann, A Primer of Advancement of Defense Costs: The Rights and Duties of Officers
13
and Corporations, 85 U. Det. Mercy L. Rev. 29, 53 (2007) (“Advancement generally refers
14
to the right of a director or officer to receive an advance for expenses that he or she incurs
15
in the legal proceeding before its final disposition. A director or officer’s entitlement to an
16
advancement of expenses is related to his or her entitlement to indemnification; however,
17
the eligibility requirements for each are distinct.”), Holley v. Nipro Diagnostics, Inc., No.
18
CA 9679-VCP, 2014 WL 7336411, at *10 (Del. Ch. Dec. 23, 2014) (“[I]ndemnification
19
and advancement ‘are separate and distinct legal actions’ and . . . the ‘right to advancement
20
is not dependent on the right to indemnification.’” (citation omitted)). Accordingly, the
21
Court holds that advancement under section 317(f) is separate and distinct from the
22
indemnification subdivisions of section 317, and thus an agent is entitled to advancement
23
under subdivision (f) if advancement is provided for by the corporation and the agent
24
provides an undertaking to repay the advancement in the event he is not entitled to
25
indemnification under section 317.
26
27
28
rely on corporate law developed in the State of Delaware given that it is identical to California corporate
law for all practical purposes.”).
10
14-CV-1566 JLS (RBB)
1
II.
Whether Defendant Is Entitled to Advancement
2
The Court now turns to whether Defendant is entitled to advancement in this case.
3
As just discussed, Defendant’s claim for advancement depends on whether (a) Plaintiff
4
provided Defendant with a right to advancement and (b) Defendant has provided an
5
undertaking to repay the advancement in the event he is not entitled to indemnification.
6
Because the Court concludes Defendant has no right to advancement, even though
7
Plaintiff’s Bylaws contain an advancement provision, the Court does not address whether
8
Defendant has provided an undertaking to repay the advancement.
9
As noted above, Plaintiff’s Bylaws expressly provide for indemnification and
10
advancement.4 As to indemnification, Section 6.1 states that the “Corporation shall
11
indemnify and hold harmless, to the fullest extent permitted by applicable law as it
12
presently exists or may hereafter be amended, any person . . . by reason of the fact that
13
he . . . is or was a director or officer of the Corporation . . . .” (Bylaws 8, ECF No. 59-4.)
14
The advancement provision of Section 6.2 is mandatory and unconditional, providing that,
15
subject to a few exceptions, the Corporation “shall pay the expenses (including attorneys’
16
fees) incurred by a director or officer in defending any proceeding in advance of its final
17
disposition . . . .” (Id.) The indemnification provision of the Bylaws, on which the
18
advancement provision is based, provides for a scope of indemnification to the fullest
19
extent of the law, which both parties agree triggers the requirements of section 317. (See
20
generally Mot., ECF No. 59-1; Opp’n, ECF No. 62.) Both the indemnification and
21
advancement provisions require the requesting party to be or have been a director or officer
22
of the Corporation. Thus, whether Defendant is entitled to advancement of his fees
23
depends in part on whether he was sued “by reason of the fact that” he was an agent, officer,
24
25
26
27
28
“It is generally accepted that corporate bylaws are to be construed according to the general rules
governing the construction of statutes and contracts. Bylaws must be given a reasonable construction and,
when reasonably susceptible thereof, they should be given a construction which will sustain their
validity . . . .” Singh v. Singh, 114 Cal. App. 4th 1264, 1294 (2004) (internal quotation marks omitted)
(citing Sanchez v. Grain Growers Ass’n, 126 Cal. App. 3d 665, 672 (1981)).
4
11
14-CV-1566 JLS (RBB)
1
or director of Plaintiff.5
2
In order to be indemnified under section 317, the action must have been brought
3
against the party “by reason of the fact that the person is or was an agent of the
4
corporation.” Cal. Corp. Code § 317 (b), (c). Courts in other jurisdictions look to the
5
allegations in the complaint when conducting the “by reason of the fact” advancement
6
analysis. See, e.g., Holley v. Nipro Diagnostics, Inc., No. CA 9679-VCP, 2014 WL
7
7336411, at *8 (Del. Ch. Dec. 23, 2014) (“[T]he ‘by reason of the fact’ analysis requires
8
looking to the allegations in the SEC’s complaint.”). While California law appears to be
9
silent on how to apply the “by reason of fact” analysis in the advancement context,
10
California courts have applied this standard to indemnification. Specifically, “by reason
11
of the fact that the person is or was an agent of the corporation” would not apply, and thus
12
indemnification is not warranted, “[w]here personal motives, not the corporate good, are
13
predominant in a transaction giving rise to an action.” Plate v. Sun-Diamond Growers,
14
225 Cal. App. 3d 1115, 1123 (1990). “‘In other words, the conduct of the agent which
15
gives rise to the claim against him must have been performed in connection with his
16
corporate functions and not with respect to purely personal matters.’”
17
omitted). “For example, ‘[i]t would . . . appear unlikely that an officer could properly claim
18
that he was entitled to indemnification as the result of litigation brought to recover short-
19
swing profits or profits from trading in the stock of his corporation on the basis of inside
20
information . . . .’” Id. (citation omitted). Accordingly, the Court will apply this reasoning
21
in the advancement context.6
Id. (citation
22
23
24
25
See, e.g., Mot. 7, ECF No. 59-1 (“At this stage, and for purposes of this summary advancement
proceeding, the Court need only assess whether [Plaintiff’s] claims against [Defendant] were asserted
against him in his capacity as a corporate agent.”); see also Homestore, Inc. v. Tafeen, 888 A.2d 204, 213–
14 (Del. 2005) (finding that the advancement provision at issue was mandatory and unconditional and still
holding a “narrow proceeding” to determine whether the party was sued in his official capacity).
5
26
The Court notes that its conclusions might have varied if it applied Delaware law interpreting the “by
reason of the fact” standard in the advancement context. In particular, Delaware law appears to be broader
than California law addressing the standard in the indemnification context. Specifically, the Delaware
Supreme Court explained that, in the advancement context, “if there is a nexus or causal connection
6
27
28
12
14-CV-1566 JLS (RBB)
1
The California Court of Appeal’s decision in Plate v. Sun-Diamond Growers is
2
instructive in this case. In Plate, defendants Branson and McElroy were officers of Sun-
3
Diamond Growers, an administrative and sales organization for roughly sixty thousand
4
growers, who initially worked with H&R Plate & Company, Inc. (“Plate”), an industrial
5
commodity food broker who was the exclusive broker for Sun-Diamond products in
6
Northern California. Id. at 119. After some time, these defendants decided to leave Sun-
7
Diamond and start their own brokerage business, eventually convincing Sun-Diamond to
8
drop Plate and hire them instead. Id. at 1120–21. Plate brought suit against Sun-Diamond,
9
McElroy, Branson, and others, and Sun-Diamond agreed to bear the cost of litigation, share
10
its counsel, and indemnify them to the extent required by section 317 against liabilities
11
arising from the litigation. Id. at 1121. In concluding that defendants Branson and
12
McElroy were not sued “by reason of the fact” they were agents of Sun-Diamond for
13
indemnification purposes, the court explained that
14
15
16
17
18
19
20
21
[t]he record establishes these defendants were sued because of
activity undertaken to establish their own business entirely
independent of Sun-Diamond, for their own personal benefit, and
not in furtherance of Sun-Diamond’s policies or objectives. Such
activity was unrelated to the performance of their corporate
duties and responsibilities at Sun-Diamond. Indeed, Branson
testified that they delayed informing Sun-Diamond of their plans
because such plans would be viewed as creating a conflict of
interest with their job performance at Sun-Diamond. Branson
and McElroy thus were sued in their capacity as individuals
pursuing their personal interests, and not by reason of the fact
they were agents of Sun-Diamond. There simply is no evidence
22
23
24
25
26
27
28
between any of the underlying proceedings contemplated by section 145(e) and one’s official corporate
capacity, those proceedings are ‘by reason of the fact’ that one was a corporate officer, without regard to
one’s motivation for engaging in that conduct.” Homestore, Inc. v. Tafeen, 888 A.2d 204, 214 (Del. 2005).
Additionally, a causal connection exists if the official’s corporate powers “were used or necessary for the
commission of the alleged misconduct.” Bernstein v. TractManager, Inc., 953 A.2d 1003, 1011 (Del. Ch.
2007). While Defendant urges the Court to adopt these standards, (Mot. 20, ECF No. 59-1), and the Court
finds Delaware law on advancement generally instructive for the reasons set forth above, supra note 3,
here there is at least some guidance from California courts. Thus the Court declines to adopt Delaware
law on this point and instead extends California indemnification law interpreting “by reason of the fact”
to the advancement analysis.
13
14-CV-1566 JLS (RBB)
1
to support a finding that the first prerequisite to indemnification
under section 317, subdivision (b), was met.
2
3
Id. at 1126.7
4
Applying the logic of Plate, the Court concludes that Defendant was not sued “by
5
reason of the fact” that he was an agent and/or officer of Plaintiff. Specifically, all of
6
Plaintiff’s claims against Defendant appear to implicate actions that predominantly benefit
7
Defendant, but do not appear to be in furtherance of the corporate good or performed in
8
connection with Defendant’s corporate functions.
9
judgment of patent application ownership is not an action against Defendant, but an action
10
to generally determine ownership of patent rights. (See SAC ¶¶ 45–48.); see also Allergia,
11
Inc. v. Bouboulis, No. 14-CV-1566 JLS (RBB), 2015 WL 11735654, at *5 (S.D. Cal. Aug.
12
17, 2015) (Sammartino, J.) (“Here, Plaintiff has shown that the parties disagree over the
13
ownership rights of the patent applications, and that such dispute warrants immediate
14
attention. A declaratory judgment by the Court, which would resolve the ownership
15
dispute, is necessary for Plaintiff and Defendant to effectively proceed with their business
16
ventures.”). Thus, this claim is not against Defendant at all, much less “by reason of the
17
fact” that he was an officer or agent of the corporation. Accordingly, the Court concludes
18
that this cause of action does not implicate the section 317 advancement analysis or any
19
right to advancement under Plaintiff’s Bylaws.
Plaintiff’s claim for declaratory
20
Furthermore, Plaintiff’s claims against Defendant for breach of fiduciary duty and
21
implied contract center on (1) Defendant’s failure to inform Plaintiff that he believed he
22
still owned some or all rights in the ’172 and ’672 patent applications, (SAC ¶¶ 50–51,
23
ECF No. 53), and (2) Defendant’s filing of allegedly secret and competing patent
24
applications and similarly not disclosing the same, (id. ¶ 52). Plaintiff’s assertions of fraud
25
26
7
27
28
The Plate Court then discussed the second prerequisite to indemnification—whether the defendants acted
in good faith—and thus that analysis is not subsumed by the court’s discussion of “by reason of the fact.”
See Plate, 225 Cal. App. 3d at 1126.
14
14-CV-1566 JLS (RBB)
1
against Defendant are based on these same allegations. (Id. ¶¶ 56–60.) The Court finds
2
that these claims for relief largely—if not entirely—implicate Defendant’s personal
3
motives, not the corporate good. Specifically, Defendant’s failure to inform Plaintiff that
4
he believed he owned some or all rights in the patent applications served to benefit him
5
(i.e., he might later assert, unbeknownst to Plaintiff, some claim for ownership rights in the
6
eventual patents). Likewise, Defendant’s alleged filing of secret and competitive patent
7
applications demonstrates a motive to retain sole ownership in those applications. And the
8
Court cannot discern how any of these alleged actions benefit Plaintiff in any way or were
9
performed by Defendant in furtherance of his corporate functions.
10
To be sure, the fact that Defendant signed certain documents transferring ownership
11
of the ’172 patent application to Plaintiff likely could not have been accomplished without
12
his role as interim President. And Defendant is accused of using his position as an officer
13
to obtain confidential information that may have been used in filing his secret patent
14
applications. Such allegations might entitle Defendant to advancement in Delaware—and
15
other—courts. Supra note 6. But based on the standard set forth in Plate, the Court
16
declines to conclude that the core of the allegations against Defendant—that he did not
17
disclose his belief that he still owned some or all rights in the ’172 and ’672 patent
18
applications, and that he secretly filed competing patent applications while working for
19
Plaintiff—were in furtherance of his corporate functions or the corporate good. Cf. Warner
20
v. Sims Metal Mgmt., No. C 13-02190 WHA, 2013 WL 4777314, at *2 (N.D. Cal. Sept. 6,
21
2013) (in the indemnification context, finding that the plaintiff was not sued by reason of
22
the fact he was an agent where “defendant allege[d] that plaintiff converted property and
23
submitted fraudulent expense reimbursements, which are purely self-serving acts that do
24
not further the corporate good”). Accordingly, the Court DENIES Defendant’s Motion for
25
Advancement of Legal Expenses.8
26
27
28
As a result, the Court need not address Plaintiff’s other arguments, such as public policy concerns or its
request to amend its SAC.
8
15
14-CV-1566 JLS (RBB)
1
2
3
4
5
CONCLUSION
For the foregoing reasons, the Court DENIES Defendant’s Motion for Advancement
of Legal Expenses. (ECF No. 59.)
IT IS SO ORDERED.
Dated: January 19, 2017
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
16
14-CV-1566 JLS (RBB)
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?